MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
The Pharma Data
JANUARY 13, 2021
14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. . NEW YORK , Jan.
Let's personalize your content